Cited 0 times in
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.